FDA ' s New Guidance for Early Alzheimer ' s Drug Development FDA ' s New Guidance for Early Alzheimer ' s Drug Development

The FDA embraces the use of biomarkers and surrogate endpoints in its most recent guidance on developing therapeutics for early Alzheimer ’s disease.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Psychiatry Source Type: news